Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. WHO established its Programme for International Drug Monitoring in response to the thalidomide disaster detected in 1961. Together with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, WHO promotes PV at the country level. At the end of 2010, 134 countries were part of the WHO PV Programme. The aims of PV are to enhance patient care and patient safety in relation to the use of medicines; and to support public health programmes by providing reliable, balanced information for the effective assessment of the risk-benefit profile of medicines.
- Reporting and learning systems for medication errors: the role of pharmacovigilance centres
The use of the WHO-UMC system for standardised case causality assessment
- The Importance of Pharmacovigilance: safety monitoring of medicinal products
Joining the WHO Programme for International Drug Monitoring
- Pharmacovigilance: ensuring the safe use of medicines
Safety of Medicines in Public Health Programmes: pharmacovigilance an essential tool